F. Lauand

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment

A. Hohl, E. P. Guedes, Thaís Gomes de Melo, 2013, Diabetology & Metabolic Syndrome.

851-P: Technology Use by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

K. Close, E. Renard, D. Bruttomesso, 2020 .

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM

E. Renard, E. Wilmot, A. Peters, 2020, Diabetes/metabolism research and reviews.

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

M. Matsuhisa, T. Danne, G. Bolli, 2020, Diabetes, obesity & metabolism.

Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System

Lauren M. Huyett, T. Ly, D. DeSalvo, 2023, Diabetes Therapy.

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

Xiaohui Guo, Junqing Zhang, Ming Liu, 2023, Diabetes, obesity & metabolism.

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

J. Rosenstock, D. Müller-Wieland, J. Westerbacka, 2020, Diabetes, obesity & metabolism.

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study

K. Khunti, J. Rosenstock, F. Giorgino, 2019, Diabetes, obesity & metabolism.

The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol

M. Mráz, M. Bonnemaire, Z. Taybani, 2024, Diabetes therapy : research, treatment and education of diabetes and related disorders.

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials

F. Lauand, Lingyu Li, Wenying Yang, 2024, Diabetes, obesity & metabolism.